financetom
Business
financetom
/
Business
/
Viavi Solutions Launches Automated Probe Microscope
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Viavi Solutions Launches Automated Probe Microscope
Mar 12, 2024 8:36 AM

11:12 AM EDT, 03/12/2024 (MT Newswires) -- Viavi Solutions ( VIAV ) said Tuesday it launched the INX 760 probe microscope, enhancing the company's optic test solutions portfolio.

The fully automated probe microscope delivers inspection and analysis of single, duplex and multi-fiber connectors in applications ranging from hyperscale data centers to metro core construction, the company said.

Viavi said it will showcase the microscope at the Optical Fiber Communication Conference and Exposition in San Diego, from March 26 to 28.

Shares of Viavi were up 0.8% in recent trading.

Price: 10.77, Change: +0.09, Percent Change: +0.80

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Mama's Creations Fiscal Q3 Earnings Decline, Revenue Increases; Shares Plunge After Hours
Mama's Creations Fiscal Q3 Earnings Decline, Revenue Increases; Shares Plunge After Hours
Dec 16, 2024
04:22 PM EST, 12/16/2024 (MT Newswires) -- Mama's Creations (MAMA) reported fiscal Q3 diluted earnings late Monday of $0.01 per share, down from $0.05 a year earlier. A single analyst surveyed by FactSet expected $0.03. Revenue for the quarter ended Oct. 31 was $31.5 million, up from $28.7 million a year earlier. Four analysts surveyed by FactSet expected $30 million....
Merus Reports First Person Dosed in Mid-Stage Petosemtamab Trial
Merus Reports First Person Dosed in Mid-Stage Petosemtamab Trial
Dec 16, 2024
04:22 PM EST, 12/16/2024 (MT Newswires) -- Merus (MRUS) said Monday the first person has been dosed in its phase 2 trial assessing petosemtamab in heavily pretreated metastatic colorectal cancer. In preclinical CRC models, petosemtamab consistently demonstrates superior activity compared to cetuximab, a mainstay therapy in mCRC, said Merus Chief Technology Officer John de Kruif. ...
Lyondellbasell Industries Insider Bought Shares Worth $380,300, According to a Recent SEC Filing
Lyondellbasell Industries Insider Bought Shares Worth $380,300, According to a Recent SEC Filing
Dec 16, 2024
04:17 PM EST, 12/16/2024 (MT Newswires) -- Robin W.T. Buchanan, Director, on December 13, 2024, executed a purchase for 5,000 shares in Lyondellbasell Industries ( LYB ) for $380,300. Following the Form 4 filing with the SEC, Buchanan has control over a total of 18,175 shares of the company, with 18,175 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1489393/000156218024008417/xslF345X05/primarydocument.xml ...
Paylocity Holding Insider Sold Shares Worth $4,138,007, According to a Recent SEC Filing
Paylocity Holding Insider Sold Shares Worth $4,138,007, According to a Recent SEC Filing
Dec 16, 2024
04:17 PM EST, 12/16/2024 (MT Newswires) -- Steven I Sarowitz, 10% Owner, Director, on December 12, 2024, sold 20,421 shares in Paylocity Holding ( PCTY ) for $4,138,007. Following the Form 4 filing with the SEC, Sarowitz has control over a total of 8,885,533 shares of the company, with 8,365,533 shares held directly and 520,000 controlled indirectly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1591698/000159169824000427/xslF345X05/wk-form4_1734383554.xml...
Copyright 2023-2026 - www.financetom.com All Rights Reserved